Categories AlphaGraphs, Consumer, Earnings

Helen of Troy delivers an earnings surprise In Q3

Helen of Troy (HELE) on Tuesday reported third-quarter earnings that surpassed analysts’ expectations. The maker of consumer products said its adjusted earnings declined 4% to $2.40 per share, higher than $2.16 per share expected by analysts.

Consolidated net sales revenue rose 2.4% to $431.1 million driven by growth in Housewares segment and online sales. This came above analysts’ consensus of $420.2 million.

Helen of Troy 3Q19 earnings snapshot

Total online sales for the quarter jumped 6%, and currently constitutes 18% of the company’s total net sales. HELE shares jumped 2.2% following the results.

CEO Julien R. Mininberg said, “We will focus on driving further improvements to our current businesses, our geographic footprint, our global shared services, and the overall strength of our organization. We will also seek to add to our Leadership Brand portfolio through acquisition.”

Helen of Troy narrowed its consolidated net sales revenue outlook for fiscal 2019 to $1.535 to $1.550 billion, representing a 3.8% to 4.8% growth. The company lowered its outlook for Housewares and Health & Home segments.

Helen of Troy smashes market estimates; raises outlook

Housewares sales are now projected to grow between 11% and 13%, compared to the prior range of 9% to 11%, while Health  & Home sales growth is anticipated between 2% and 4%, compared to the prior guidance of 5% To 7%.

Beauty segment will see a net sales decline in the low- to mid-single digits, as projected earlier.

Helen of Troy now expects GAAP diluted EPS from continuing operations of $6.35 to $6.51 for the full year, and non-GAAP adjusted diluted EPS from continuing operations in the range of $7.70 to $7.95,

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference, and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top